BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 26775730)

  • 1. The Wnt signaling pathway in cancer.
    Duchartre Y; Kim YM; Kahn M
    Crit Rev Oncol Hematol; 2016 Mar; 99():141-9. PubMed ID: 26775730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic Manipulation of Wnt Signaling and Cancer Stem Cells.
    Duchartre Y; Kim YM; Kahn M
    Methods Mol Biol; 2017; 1613():463-478. PubMed ID: 28849572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt Signaling in Stem Cells and Tumor Stem Cells.
    Kahn M
    Semin Reprod Med; 2015 Sep; 33(5):317-25. PubMed ID: 26251120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms promoting physiological cells progression into tumorigenesis.
    Korbut E; Ptak-Belowska A; Brzozowski T
    J Physiol Pharmacol; 2012 Dec; 63(6):565-70. PubMed ID: 23388471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft.
    Martins-Neves SR; Paiva-Oliveira DI; Fontes-Ribeiro C; Bovée JVMG; Cleton-Jansen AM; Gomes CMF
    Cancer Lett; 2018 Feb; 414():1-15. PubMed ID: 29126913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells.
    Seto K; Sakabe T; Itaba N; Azumi J; Oka H; Morimoto M; Umekita Y; Shiota G
    Anticancer Res; 2017 Jul; 37(7):3569-3579. PubMed ID: 28668848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel Anti-Cancer Stem Cells compound optimized from the natural symplostatin 4 scaffold inhibits Wnt/β-catenin signaling pathway.
    Liu S; Gao X; Zhang L; Qin S; Wei M; Liu N; Zhao R; Li B; Meng Y; Lin G; Lu C; Liu X; Xie M; Liu T; Zhou H; Qi M; Yang G; Yang C
    Eur J Med Chem; 2018 Aug; 156():21-42. PubMed ID: 30006166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt/β-catenin pathway mediates (-)-Epigallocatechin-3-gallate (EGCG) inhibition of lung cancer stem cells.
    Zhu J; Jiang Y; Yang X; Wang S; Xie C; Li X; Li Y; Chen Y; Wang X; Meng Y; Zhu M; Wu R; Huang C; Ma X; Geng S; Wu J; Zhong C
    Biochem Biophys Res Commun; 2017 Jan; 482(1):15-21. PubMed ID: 27836540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Wnt/β-catenin signaling pathway in cancer.
    Zhang Y; Wang X
    J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the cancer stem cell phenotype: A step forward in the therapeutic management of cancer.
    Wong ALA; Bellot GL; Hirpara JL; Pervaiz S
    Biochem Pharmacol; 2019 Apr; 162():79-88. PubMed ID: 30689981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer.
    Song L; Li Y; He B; Gong Y
    Clin Colorectal Cancer; 2015 Sep; 14(3):133-45. PubMed ID: 25799881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Cancer Stem Cells Pathways for the Effective Treatment of Cancer.
    Dwivedi AR; Thakur A; Kumar V; Skvortsova I; Kumar V
    Curr Drug Targets; 2020; 21(3):258-278. PubMed ID: 31433755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Delivery of a Wnt Pathway Inhibitor Toward CSCs Requires Stable Liposome Encapsulation and Delayed Drug Release in Tumor Tissues.
    Li C; Liang Y; Cao J; Zhang N; Wei X; Tu M; Xu F; Xu Y
    Mol Ther; 2019 Sep; 27(9):1558-1567. PubMed ID: 31350188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics.
    Tabatabai R; Linhares Y; Bolos D; Mita M; Mita A
    Target Oncol; 2017 Oct; 12(5):623-641. PubMed ID: 28653295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt signaling in cancer.
    Zhan T; Rindtorff N; Boutros M
    Oncogene; 2017 Mar; 36(11):1461-1473. PubMed ID: 27617575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug discovery approaches to target Wnt signaling in cancer stem cells.
    Curtin JC; Lorenzi MV
    Oncotarget; 2010 Nov; 1(7):563-577. PubMed ID: 21317452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ginsenoside-Rb1 targets chemotherapy-resistant ovarian cancer stem cells via simultaneous inhibition of Wnt/β-catenin signaling and epithelial-to-mesenchymal transition.
    Deng S; Wong CKC; Lai HC; Wong AST
    Oncotarget; 2017 Apr; 8(16):25897-25914. PubMed ID: 27825116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sonic hedgehog and Wnt/β-catenin pathways mediate curcumin inhibition of breast cancer stem cells.
    Li X; Wang X; Xie C; Zhu J; Meng Y; Chen Y; Li Y; Jiang Y; Yang X; Wang S; Chen J; Zhang Q; Geng S; Wu J; Zhong C; Zhao Y
    Anticancer Drugs; 2018 Mar; 29(3):208-215. PubMed ID: 29356693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer stem cells - A therapeutic target?
    Maitland NJ; Collins AT
    Curr Opin Mol Ther; 2010 Dec; 12(6):662-73. PubMed ID: 21154158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in the study of targeted drug delivery systems for cancer stem cells].
    Qiao MX; Zhang XJ; Shuang BA; Hu HY; Zhao XL; Chen DW
    Yao Xue Xue Bao; 2013 Apr; 48(4):477-83. PubMed ID: 23833932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.